Stoke Therapeutics stock reports USD 9.33 million Q2 revenue
Published on 09/30/2026 at 15:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Stoke Therapeutics stock is anchored by USD 9.33 million in second-quarter 2026 revenue, while the company reported a loss of USD 0.93 per share. The result paired a revenue beat with a deeper-than-expected earnings loss, giving the clinical-stage biotechnology company a mixed financial checkpoint on September 23, 2026.
Revenue beat expectations
According to MarketBeat on September 23, 2026, Stoke reported quarterly revenue of USD 9.32 million against analyst estimates of USD 4.89 million. The same report said quarterly EPS came in at minus USD 0.93, compared with a consensus loss of USD 0.80, a shortfall of USD 0.13 per share.
The company is developing RNA-based medicines for severe genetic diseases through its TANGO platform, with zorevunersen as its lead program for Dravet syndrome. Stoke's investor page describes the compound as being in clinical testing and identifies autosomal dominant optic atrophy as a second disease focus.
Analysts keep targets elevated
MarketBeat reported that 10 of 11 analysts carried Buy ratings and one carried a Sell rating, producing a Moderate Buy consensus and a USD 44.25 average 12-month target. JPMorgan initiated coverage on August 21, 2026, with an Overweight rating and a USD 40.00 target, while Canaccord cut its target from USD 60.00 to USD 58.00 on August 4, 2026.
The target spread shows why the development pipeline matters more than near-term earnings for valuation. The USD 44.25 consensus target stands above the latest Nasdaq quote, but the company remains loss-making while it advances clinical programs toward potential regulatory milestones.
Nasdaq quote stays below yearly high
Stoke was last at USD 25.88 on Nasdaq on September 29, 2026 at 4:00 p.m. ET. The stock's 52-week range was USD 20.32 to USD 40.22, and market capitalization stood at USD 1.7 billion on the same date.
Investing.com lists November 10, 2026 as the next earnings date. That event will give investors a fresh comparison between revenue delivery, cash use and progress in the development pipeline.
Stoke Therapeutics at a glance
- Company: Stoke Therapeutics, Inc.
- Ticker: STOK
- Primary exchange: Nasdaq Global Select Market
- Market capitalization: USD 1.7 billion (as of September 29, 2026)
- 52-week range: USD 20.32-USD 40.22 (as of September 29, 2026)
- Sector / Industry: Healthcare / Biotechnology
- Next earnings date: November 10, 2026
